Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 12/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 2/20 | 0.40 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4983425 | 0.89 | PNMT (0.48) | PNMTFFAR1DPP4DPP7FDFT1 | |
| SCHEMBL4986912 | 0.86 | FFAR1 (0.46) | PNMTFFAR1KMO | |
| SCHEMBL4986080 | 0.84 | FFAR1 (0.44) | PNMTFFAR1 | |
| SCHEMBL4990543 | 0.84 | SLC6A2 (0.46) | FDFT1TSHR | |
| SCHEMBL4990340 | 0.83 | PNMT (0.57) | PNMTFFAR1DPP4DPP7KMO | |
| SCHEMBL4992928 | 0.82 | PNMT (0.53) | PNMTFFAR1 | |
| SCHEMBL4995226 | 0.81 | FFAR1 (0.42) | PNMTFFAR1 | |
| SCHEMBL2029896 | 0.79 | DPP4 (0.56) | PNMTFFAR1DPP4DPP7KMO | |
| SCHEMBL2029893 | 0.79 | DPP4 (0.56) | PNMTFFAR1DPP4DPP7KMO | |
| SCHEMBL29478406 | 0.79 | DPP4 (0.56) | PNMTFFAR1DPP4DPP7KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | claimed |
| EP-1553101-B1 | N-ACETYLGLUCOSAMINE DERIVATIVES AND USE THEREOF | KAO CORP (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-20080293673-A1 | N-ACETYGLUCOSAMINE DERIVATIVES AND USE THEREOF | KAO CORPORATION | 2008-11-27 | — | — | US | disclosed |
| US-7393937-B2 | N-acetylglucosamine derivatives and use thereof | KAO CORPORATION (JP) | 2008-07-01 | — | — | US | disclosed |
| US-7388023-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WANER-LAMBERT COMPANY LLC (US) | 2007-06-07 | — | — | US | disclosed |
| US-7179934-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1667957-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA-PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20060020127-A1 | N-acetylglucosamine derivatives and use thereof | KANEBO COSMETICS INC. (JP) | 2006-01-26 | — | — | US | disclosed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-05-12 | — | — | US | disclosed |
| WO-2005030700-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, SCN1A, OPRD1 | PNMT 2239/4885FFAR1 2235/4885DPP4 2680/4885 |
| US-20060020127-A1 | N-acetylglucosamine derivatives and use thereof | FUT6, B3GNT2, FUT5 | PNMT 4417/4885FFAR1 696/4885DPP4 2561/4885 |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | SCN2A, OPRD1, SCN1A | PNMT 1531/4885FFAR1 1923/4885DPP4 3263/4885 |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | PNMT 2122/4885FFAR1 2117/4885DPP4 2672/4885 |
| US-20080293673-A1 | N-ACETYGLUCOSAMINE DERIVATIVES AND USE THEREOF | B3GNT2, FUT6, FUT5 | PNMT 4461/4885FFAR1 612/4885DPP4 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.